Shorted

TELIX PHARMACEUTICAL ORDINARY (TLX) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Why Is Telix Pharmaceuticals (ASX:TLX) Quoting Additional Shares?

Highlights Telix Pharmaceuticals has applied to the ASX to quote additional ordinary fully paid shares. The newly quoted shares form part of the company's ongoing capital management activities. The application reflects continued corporate administration as Telix advances its global precision medicine strategy. Telix Pharmaceuticals Limited (ASX:TLX) has submitted an application to the Australian Securities Exchange to quote additional ordinary fully paid shares, conti...

Continue reading
Kalkine
Neutral
just now

Why Is Telix Pharmaceuticals (ASX:TLX) Lifting Sentiment Across ASX Biotech Stocks?

Highlights Telix Pharmaceuticals has received positive FDA feedback supporting the next stage of its prostate cancer therapy programme. Imricor Medical Systems expanded the approved use of its MRI-guided cardiac ablation products in the United States. Recent regulatory progress continues strengthening confidence across Australia's healthcare and biotechnology sector. Telix Pharmaceuticals Ltd (ASX:TLX) has strengthened market confidence after receiving encouraging reg...

Continue reading
Kalkine
Neutral
just now

Why Is Telix Pharmaceuticals (ASX:TLX) Standing Out This Year?

Highlights Telix Pharmaceuticals, Lindian Resources and GemLife Communities represent different growth stories across healthcare, mining and property development. Commercial execution and business expansion remain central themes for all three companies. Strong management alignment continues to attract attention across selected Australian growth companies. Telix Pharmaceuticals, Lindian Resources...

Continue reading
Kalkine
Neutral
just now

Telix Pharmaceuticals (ASX:TLX): Why Radiopharma Momentum Is Back in Focus

Highlights Radiopharma momentum is reshaping the conversation around ASX healthcare stocks as markets balance clinical demand with a tougher macro backdrop. Telix Pharmaceuticals (ASX:TLX), Pro Medicus (ASX:PME), CSL (ASX:CSL), ResMed (ASX:RMD) and 4DMedical (ASX:4DX) highlight how company-specific execution is driving attention. Market participants are placing greater emphasis on cash-flow quality, balance-sheet resilience and visible catalysts rather than broad sect...

Continue reading
Kalkine
Neutral
just now

Telix Pharmaceuticals (ASX:TLX): Why Software Healthcare Duration Is Turning Heads

Highlights Software healthcare duration is reshaping how readers assess earnings runway, cash-flow quality and execution across growth-focused sectors. Telix Pharmaceuticals (ASX:TLX), Life360 (ASX:360), Megaport (ASX:MP1), Xero (ASX:XRO) and Pro Medicus (ASX:PME) highlight the growing importance of company-specific evidence. The current market backdrop is rewarding operational discipline while placing greater scrutiny on long-duration growth narratives. Th...

Continue reading
Kalkine
Neutral
just now

Telix (ASX:TLX): Why Is ASX Healthcare Finding Bright Spots?

Highlights Telix and ResMed are standing out while parts of the healthcare sector face pressure. Radiopharmaceuticals and sleep-health devices are giving the sector fresh momentum. Stronger execution is helping select healthcare names counter wider market gloom. Telix and ResMed are bright spots in Australian healthcare, showing how specialised medical markets, commercial execution and resilient demand can counter wider sector weakne...

Continue reading
Kalkine
Neutral
just now

Is Telix Pharmaceuticals (ASX:TLX) the ASX Mid-Cap Health Leader?

Highlights Telix Pharmaceuticals (ASX:TLX) strengthens its position as a leading ASX mid-cap healthcare name. Illuccix and Gozellix drive expanding commercial footprint across major global markets. Radiopharmaceutical sector momentum supports broader ASX 200 healthcare segment strength. Telix Pharmaceuticals has strengthened its ASX mid-cap healthcare position through global expansion of Illuccix and Gozellix, marking its transition into a commercially established radiopharmaceutical gr...

Continue reading
Kalkine
Neutral
just now

Telix Trial Update Puts Theranostics Back in Focus

Highlights Telix reported encouraging safety data from its late-stage prostate cancer therapy trial. A new United Imaging agreement may support broader theranostic workflow development. The update strengthens attention on radiopharmaceuticals, imaging and oncology innovation. Telix reported encouraging ProstACT safety data and expanded an imaging partnership, reinforcing attention on radiopharmaceuticals, theranostics and oncology innovation across Australia’s healthcare market. Austral...

Continue reading
Kalkine
Neutral
just now

Is Telix Pharma (ASX:TLX) in ASX 200 Market Focus?

Highlights Telix Pharmaceuticals reflects valuation-related market attention. Biotechnology developments influence healthcare sector activity. Market participation aligns with broader ASX healthcare trends. Telix Pharmaceuticals reflects valuation-focused attention within the ASX healthcare sector, highlighting biotechnology participation and trends across ASX 100 and ASX 200 indices. The healthcare and biotechnology sector represents a vital component of the Australian equity landscape...

Continue reading